Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells”-Reference-Cited by-同舟云学术

Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells”

Published:2013-06-05 Issue:188 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bilican Bilada¹²,Serio Andrea¹²,Barmada Sami J.³⁴,Nishimura Agnes Lumi⁵,Sullivan Gareth J.²,Carrasco Monica⁶,Phatnani Hemali P.⁶,Puddifoot Clare A.⁷,Story David¹²,Fletcher Judy²,Park In-Hyun⁸,Friedman Brad A.⁹,Daley George Q.¹⁰,Wyllie David J. A.⁷,Hardingham Giles E.⁷,Wilmut Ian²,Finkbeiner Steven³⁴,Maniatis Tom⁶,Shaw Christopher E.⁵,Chandran Siddharthan¹²¹¹

Affiliation:

1. Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh EH16 4SB, UK.

2. Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4SB, UK.

3. Taube-Koret Center, Hellman Program, and Rodenberry Stem Cell Program, Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.

4. Departments of Neurology and Physiology, University of California, San Francisco, San Francisco, CA 94143, USA.

5. Institute of Psychiatry, Medical Research Council Centre for Neurodegeneration Research, King’s College London, London SE5 8AF, UK.

6. Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.

7. Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, UK.

8. Yale Stem Cell Center, Department of Genetics, Yale School of Medicine, New Haven, CT 06520, USA.

9. Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.

10. Department of Biological Chemistry and Molecular Pharmacology, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA.

11. Centre for Neuroregeneration, University of Edinburgh, Edinburgh EH16 4SB, UK.

Abstract

Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference5 articles.

1. Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells

2. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability

3. Automated microscope system for determining factors that predict neuronal fate.;Arrasate M.;Proc. Natl. Acad. Sci. U.S.A.,2005

4. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

5. Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Platform to Understand Amyotrophic Lateral Sclerosis (ALS) and Extend Human Motor Neurons Longevity;International Journal of Morphology;2019-12

2. Gene therapy to target ER stress in brain diseases;Brain Research;2016-10

3. Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development;Acta Neuropathologica;2013-12-05

4. The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation;Stem Cells and Development;2013-12

5. Using human induced pluripotent stem cells to treat retinal disease;Progress in Retinal and Eye Research;2013-11